Evidence map›Paper›PMID 37991382›Full record

ArticleInfection and immunity2023

Evaluating vaccine-elicited antibody activities against

Mary C Gray, Keena S Thomas, Evan R Lamb, Lacie M Werner, Kristie L Connolly, Ann E Jerse, Alison K Criss

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Effectiveness of the four-component protein-based meningococcal vaccine againstCanada communicable disease report = Releve des maladies transmissibles au Canada · 2025
    Article
  8. Article
  9. Article
  10. Protection againstFrontiers in immunology · 2025
    Article
  11. Article
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mary C Gray *Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Keena S Thomas *Department of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Evan R LambDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Lacie M WernerDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.
Kristie L ConnollyDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.
Ann E JerseDepartment of Microbiology and Immunology, Uniformed Services University, Bethesda, Maryland, USA.
Alison K CrissDepartment of Microbiology, Immunology, and Cancer Biology, University of Virginia School of Medicine, Charlottesville, Virginia, USA.ORCID 0000-0001-7738-3757
University of Virginia · USUniformed Services University of the Health Sciences · US

Funding

INFECTIOUS DISEASES TRAINING PROGRAMT32AI007046 · NIAID · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Alison K Criss, William A Petri · 1985 to 2026
$15.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
The Gonorrhea Vaccine Cooperative Research CenterU19AI144180 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI JERSE, ANN E. · 2019 to 2023
$10.7M
Survival of Neisseria gonorrhoeae after primary human neutrophil challengeR01AI097312 · NIAID · UNIVERSITY OF VIRGINIA · PI CRISS, ALISON K · 2012 to 2022
$4.6M
Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae.U01AI162457 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DUNCAN, JOSEPH A · 2021 to 2025
$3.9M
Survival of Neisseria gonorrhoeae after primary human neutrophil challengeR37AI097312 · NIAID · UNIVERSITY OF VIRGINIA · PI Alison K Criss · 2025 to 2026
$1.1M
Complement-independent role of C4 binding protein in gonococcal survival from human neutrophilsR21AI157539 · NIAID · UNIVERSITY OF VIRGINIA · PI CRISS, ALISON K · 2021 to 2022
$435k
NIAID NIH HHS R01 AI097312NIAID NIH HHS R21 AI157539NIAID NIH HHS R37 AI097312NIAID NIH HHS T32 AI007046NIAID NIH HHS U01 AI162457NIAID NIH HHS U19 AI144180NIGMS NIH HHS T32 GM007267
6 · The paper itself

Abstract

The bacterial pathogen

Indexed as

GonorrheaMeningococcal InfectionsMeningococcal VaccinesNeisseria meningitidisNeisseria meningitidis, Serogroup BAnimalsAntibodiesAntibodies, BacterialAntigens, BacterialBacterial VaccinesHumansMiceNeisseria gonorrhoeaeVaccines, CombinedAntibodiesAntibodies, BacterialAntigens, BacterialBacterial VaccinesMeningococcal VaccinesVaccines, Combinedantibodycomplementimaging flow cytometryNeisseria gonorrhoeaeopsonophagocytic killingserum bactericidal activityvaccine

Identifiers

PMID37991382
PMCPMC10715150
OpenAlexW4388901756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.